Bntx stocks.

J.P. Morgan's assessment implies potential challenges for in keeping up with performance expectations compared to its broader coverage group. Price Action: BNTX shares are down 2.13% at $98.27 on ...BioNTech SE BNTX has reported Q3 revenues of €895.3 million ($974.49 million), sharply down from €3.461 billion a year ago. Analysts estimated $1.06 billion in sales. For the nine months ...The share price of BioNTech SE (BNTX) now. What analysts predict: $142.42. 52-week High/Low: $188.99 / $88. 50/200 Day Moving Average: $101.74 / $113.19. This figure corresponds to the Average Price over the previous 50/200 days. For BioNTech stocks, the 50-day moving average is the resistance level today.About BioNTech SE ADR BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac,...

The 16 analysts offering 1 year price forecasts for BNTX have a max estimate of — and a min estimate of —. Analyst rating Based on 18 analysts giving stock ratings to BNTX in the past 3 months.BNTX: BioNTech SE Stock Price Quote - NASDAQ GS - Bloomberg Subscribe S&P 500 4,556.62 +0.41% Nasdaq 14,265.86 +0.46% Crude Oil 76.49 –0.79% US 10 Yr 100.31 +2,138.69% Euro 1.09 –0.09% Dow...BioNTech SE (BNTX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock BioNTech SE | Nasdaq: BNTX | Nasdaq

BioNTech (NASDAQ:BNTX) is scheduled to announce Q2 earnings results on Monday, August 7th, before market open.The consensus EPS Estimate is -$0.82 and the consensus Revenue Estimate is $797.44M ...The stock of BioNTech SE ADR (BNTX) has gone down by -2.01% for the week, with a 3.63% rise in the past month and a -20.46% drop in the past quarter. The volatility ratio for the week is 3.45%, and the volatility levels for the past 30 days are 3.21% for BNTX. The simple moving […]

BioNTech (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock rally from about $80 at the end of 2020 to levels of almost $420 currently ...The company's average rating score is 2.30, and is based on 4 buy ratings, 5 hold ratings, and 1 sell rating. Price Target Upside/Downside. According to ...May 8, 2023 · On today's stock market, BNTX stock dipped 0.4% and closed at 108.05. BNTX Stock: Lower Boosting Levels Expected. The Pfizer -partnered Covid shot is BioNTech's only commercial product. BioNTech's ... BNTX: BioNTech SE - Stock Price, Quote and News - CNBCGet BioNTech SE (BNTX.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

The share price of BioNTech SE (BNTX) now. What analysts predict: $142.42. 52-week High/Low: $188.99 / $88. 50/200 Day Moving Average: $101.74 / $113.19. This figure corresponds to the Average Price over the previous 50/200 days. For BioNTech stocks, the 50-day moving average is the resistance level today.

BioNTech - BNTX - Stock Price Today - Zacks BioNTech (BNTX) (Delayed Data from NSDQ) $97.16 USD -1.67 (-1.69%) Updated Nov 21, 2023 04:00 PM ET After-Market: $97.18 +0.02 (0.02%) 7:58 PM ET...

Stocks with records like Novavax's are considered speculative. In the fourth quarter, NVAX stock analysts expect a per-share gain of 16 cents. On an adjusted basis, they expect a 60-cent loss.Over the past 3 months, 5 analysts have published their opinion on BioNTech (NASDAQ:BNTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a ...Like many other biotech names, BNTX stock has fallen 30 % YTD. Shares are trading at 4.2 times forward earnings and only 1.7 times sales. At present, the 12-month median price forecast for ...The company's average rating score is 2.30, and is based on 4 buy ratings, 5 hold ratings, and 1 sell rating. Price Target Upside/Downside. According to ...BioNTech (NASDAQ:BNTX) stock rose 4.7% after the drugmaker cut its 2023 revenue target on lower demand for the COVID-19 vaccine made with Pfizer (NYSE:PFE) but said the impact from write-downs at ...BioNTech ( BNTX ): Despite recent losses, it’s seen as a cheap biotech stock with potential, trading at low free cash flow multiples and projecting healthy upside. Halozyme ( HALO ): Showed ...The company's average rating score is 2.30, and is based on 4 buy ratings, 5 hold ratings, and 1 sell rating. Price Target Upside/Downside. According to ...

SIGA Technologies, Inc. (NASDAQ:SIGA) ranks 11th in our list of the most undervalued biotechnology stocks to buy according to hedge funds. Insider Monkey’s proprietary database of 920 hedge ...BioNTech SE stock performance at a glance. Check BioNTech SE’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.BNTX Earnings Date and Information. BioNTech last issued its quarterly earnings results on November 6th, 2023. The reported $0.67 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $1.26. The business earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million.Among the 386 stocks in the Biotech industry, MRNA is ranked #62, while BNTX is ranked #27. Beyond what is stated above, we have also rated the stocks for Value, Growth, Momentum, Stability, and ...Medical - Biomedical and Genetics. $23.493B. $18.242B. BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany. Stock Name. Country. Market Cap.

BioNTech SE BNTX is expected to report its fourth-quarter 2022 results later this month. BioNTech's earnings surprise history has been decent so far, having surpassed expectations in three of the ...See the latest BioNTech SE ADR stock price (BNTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

CEO. Website. 2008. 5,700. Ugur Sahin. https://www.biontech.de. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is …Discover historical prices for BNTX stock on Yahoo Finance. View daily, weekly or monthly format back to when BioNTech SE stock was issued. Of the 299 institutional investors that purchased BioNTech stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Temasek Holdings Private Ltd ($3.98M), Baillie Gifford & Co. ($2.54M), Flossbach Von Storch AG ($2.45M), Artisan Partners Limited Partnership ($2.19M), Envestnet Asset ...Dec 1, 2023 · BNTX Earnings Date and Information. BioNTech last issued its quarterly earnings results on November 6th, 2023. The reported $0.67 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $1.26. The business earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million. Average Volume (3M) 692.88K. Market Cap. $23.63B. Enterprise Value $9.96B. Total Cash (Recent Filing) €13.88B. Total Debt (Recent Filing) €212.20M. Price to Earnings (P/E) 8.5. Beta 0.70. Next Earnings.Real time BioNTech Se (BNTX) stock price quote, stock graph, news & analysis.BNTX stock analysts expected 4.44 billion euros in sales for the year. Germany-based BioNTech noted fewer people are receiving primary vaccinations and population-wide boosting is much lower.

BioNTech Free Cash Flow Forecast for 2023 - 2025 - 2030. In the last three years, Free Cash Flow for BioNTech has grown by 5772.67%, going from $-237.10M to $13.45B. In the coming year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $20.35B – an increase of 51.34%. Over the next eight years, experts anticipate ...

BioNTech SE stock performance at a glance. Check BioNTech SE’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.

BNTX stock analysts projected a per-share loss of 30 cents. BioNTech blamed write-offs to partner Pfizer for the profit and sales hits. On today's stock market, BNTX stock toppled 7.5% to 98.50 ...Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, BioNTech has an average ...However, it's significantly underperforming BNTX stock's YTD return of 258.1%. What was Moderna's FY22 Outlook Presented in FQ3? Moderna presented a reasonably strong FY22 guidance in its FQ3 ...BNTX - BioNTech SE Stock quote - CNNMoney.com Markets Tech Media Success Video BioNTech SE (NASDAQ:BNTX) 99.38 Delayed Data As of 3:59pm ET +1.08 / +1.10% Today’s Change 88.00 Today |||...Holder Shares Date Reported % Out Value; Vanguard Horizon Fund-Capital Opportunity Fund: 2,234,636: Sep 29, 2023: 0.94%: 222,122,821: Primecap Odyssey Aggressive ...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. $82.33 -0.02 -0.02%. -0.07. $180.07. BioNTech SE American Depositary Share ...The Zacks database contains over 10,000 stocks. All of those stocks are classified into three groups: Sector, M Industry and X Industry. There are 17 Sectors, 60 different M Industries, and 265 X ...BioNTech (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, saw its stock price decline by almost 34% over the last month, considerably underperforming ...Term Box: Best BioNTech SE - ADR forecast, BNTX stock price prediction, BNTX forecast, BioNTech SE - ADR finance tips, BNTX prediction, BioNTech SE - ADR analyst report, BNTX stock price predictions 2023, BioNTech SE - ADR stock forecast, BNTX forecast tomorrow, BioNTech SE - ADR technical analysis, BNTX stock future price, BioNTech SE - ADR projections, BioNTech SE - ADR market prognosis ... The analyst Jessica Fye also trims her price target on BNTX to $99 from $106 per share, arguing that the sinking estimations for the company's COVID-19 vaccine business have hurt the stock "and ...

16 Oct 2023 ... Topline. Stocks of Pfizer and other Covid vaccine makers like BioNTech and Moderna fell in premarket trading Monday after the company slashed ...BNTX stock is another name to buy after stellar earnings report. For Q3 2020, the company reported 135% top-line growth. While BNTX stock has already surged by 106% in the last six months, I ...About BioNTech SE ADR BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac,...Instagram:https://instagram. c3.ai stock earningstwlo stokab celleraalgorithmic trading apps 3 Wall Street analysts have issued twelve-month price objectives for Better Therapeutics' stock. Their BTTX share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 2,791.6% from the stock's current price.3. BioNTech. Per its coronavirus vaccine collaboration with Pfizer, BioNTech ( BNTX 1.40%) is the only company on this list that's currently earning revenue as a result of its sales of mRNA ... ira options tradingvalue of 1921 silver dollar coin About BioNTech SE ADR BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac,... books for communication Dec 1, 2023 · BNTX Earnings Date and Information. BioNTech last issued its quarterly earnings results on November 6th, 2023. The reported $0.67 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $1.26. The business earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million. BioNTech SE. Analyst Report: BioNTech SE BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as ...The share price of BioNTech SE (BNTX) now. What analysts predict: $142.42. 52-week High/Low: $188.99 / $88. 50/200 Day Moving Average: $101.74 / $113.19. This figure corresponds to the Average Price over the previous 50/200 days. For BioNTech stocks, the 50-day moving average is the resistance level today.